Starrett J E, Tortolani D R, Hitchcock M J, Martin J C, Mansuri M M
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492.
Antiviral Res. 1992 Sep;19(3):267-73. doi: 10.1016/0166-3542(92)90084-i.
9-(2-Phosphonylmethoxyethyl)adenine (PMEA; 1) was acylated with chloromethyl pivalate to afford bis(pivaloyloxymethyl) PMEA (2). The ester prodrug demonstrated enhanced in vitro potency against HSV-2 greater than 150-fold higher than the parent compound. The antiviral activity of 2 was 50-fold better than PMEA against HSV-1, and equipotent against HIV and HCMV. The toxicity of 2 was studied in both resting and growing cells.
9-(2-膦酰甲氧基乙基)腺嘌呤(PMEA;1)与新戊酰氯甲酯进行酰化反应,得到双(新戊酰氧基甲基)PMEA(2)。该酯前药对单纯疱疹病毒2型(HSV-2)的体外效力增强,比母体化合物高150倍以上。化合物2对HSV-1的抗病毒活性比PMEA高50倍,对HIV和人巨细胞病毒(HCMV)的活性相当。在静息细胞和生长细胞中都研究了化合物2的毒性。